The shortage of available organs for transplantation has driven up use of high-risk donor livers. New research published in the October issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases, reported that high volume transplant centers more frequently utilized livers with a high donor risk index, but achieved better risk-adjusted graft and recipient survival rates compared with lower volume centers.
During the past forty years the liver transplantation field has made remarkable progress in improving quality of life, with the mortality rate for waitlisted candidates and size of the national waitlist decreasing over the last ten years. According to the Organ Procurement and Transplantation Network (OPTN), more than 110,000 liver transplantations have been performed in the U.S. since 1988. However, despite these strides nearly 2,000 candidates on the waitlist die each year.
To address the critical issue of organ shortage, transplant centers in the U.S. have expanded criteria that qualify more high-risk livers—what was previously known as marginal or compromised organs—from deceased donors. Medical experts believe earlier transplantation with higher-risk organs outweigh the associated risk of remaining on the waiting list and measure donor suitability using the donor risk index (DRI)—an assessment of donor characteristics that includes age, race, and cause of death. Typically, a lower DRI is associated with better outcome.
For the present study Dr. Shimul A. Shah and colleagues from the University of Massachusetts Medical School identified 31,587 deceased donor liver transplants from the Scientific Registry of Transplant Recipients database between 2002 and 2008. Recipients who were 18 years of age and older were included, and partial or multiple liver transplants were excluded. Over 100 transplant centers were included with high volume centers (HVC) conducting 78-215 procedures annually; medium volume centers (MVC) at 49-77, and low volume centers (LVC) at 5-48.
Results showed that HVC utilized donors with higher mean DRI at 2.07 compared to MVC and LVC at 2.01 and 1.91, respectively. Centers with greater procedure volume were found to have decreased risk of graft failure and recipient death. "Our study was the first to demonstrate the survival benefits associated with center-specific procedure volume and DRI," said Dr. Shah, a surgeon at UMass Memorial Medical Center. "With increasing numbers of waitlist candidates and critical shortage of available organs, it is vital that every available liver be fully utilized and we continue to evaluate outcomes with high-risk donor organs."
In a related editorial also published in this month's issue of Liver Transplantation, Dr. Robert Merion, Professor of Surgery at the University of Michigan and President of the Arbor Research Collaborative for Health in Ann Arbor said, "Studies such as Shah et al. advance our understanding of associations between facility-level characteristics and outcomes. There is much knowledge of transplant candidates and their donors, but now we must focus more deeply on facility practices in order to dissect out the center effect in the field of liver transplantation."
These studies are published in Liver Transplantation. Media wishing to receive a PDF of the articles may contact email@example.com.
Full citation: "Impact of Center Volume on Increased Risk Liver Transplant Outcomes." Deepak K. Ozhathil, You Fu Li, Jillian K. Smith, Jennifer F. Tseng, Reza F. Saidi, Adel Bozorgzadeh, Shimul A. Shah. Liver Transplantation; Published Online: September 26, 2011 (DOI: 10.1002/lt.22343) Print Issue Date: October 2011. http://onlinelibrary.wiley.com/doi/10.1002/lt.22343/abstract.
Full citation: "It's Time to Look Inward." Robert M. Merion. Liver Transplantation; Published Online: September 26, 2011 (DOI: 10.1002/lt.22366) Print Issue Date: October 2011. http://onlinelibrary.wiley.com/doi/10.1002/lt.22366/abstract.
Author Contact: To arrange an interview with Dr. Shah, please contact Robert Brogna with UMass Memorial Medical Center at firstname.lastname@example.org or 508-793-5394.
About the Journal
Liver Transplantation. is published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society . Since the first application of liver transplantation in a clinical situation was reported more than twenty years ago, there has been a great deal of growth in this field and more is anticipated. As an official publication of the AALSD and the ILTS, Liver Transplantation. delivers current, peer-reviewed articles on surgical techniques, clinical investigations and drug research — the information necessary to keep abreast of this evolving specialty. For more information, please visit Liver Transplantation.
Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world's most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.
What: The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Founded in 1950, AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD has grown into an international society responsible for all aspects of hepatology, and the annual meeting attracts 8,500 physicians, surgeons, researchers, and allied health professionals from around the world.
The Liver Meeting® is the premier meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies.
When: November 4-8, 2011
Moscone West Convention Center
San Francisco, California
Contact: Please contact Ann Haran at 703-299-9766 or email@example.com to obtain a press pass for this event.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.